Brand Name

Triptodur

Generic Name
Triptorelin
View Brand Information
FDA approval date: September 08, 2017
Form: Kit

What is Triptodur (Triptorelin)?

TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty . TRIPTODUR is a gonadotropin releasing hormone agonist indicated for the treatment of pediatric patients 2 years and older with central precocious puberty.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)
Who is this study for: Patients with Prostate Cancer
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Goserelin, Histrelin, Leuprolide & Triptorelin, Androgen Deprivation Therapy + Nilutamide, Flutamide, & Bicalutamide, Degarelix, Androgen Deprivation Therapy + Docetaxel +/- Prednisone, Androgen Deprivation Therapy + Abiraterone + Prednisone, Androgen Deprivation Therapy + Abiraterone + Methylprednisolone, Androgen Deprivation Therapy + Apalutamide, Androgen Deprivation Therapy + Enzalutamide
Study Phase: Phase 2/Phase 3

Summary: This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinica...

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (...

LIBELULA™: An Open-label, Single-arm, Multi-center, Phase 3 Study on the Efficacy, Safety, and Pharmacokinetics of Debio 4326, a Triptorelin 12-month Formulation, in Pediatric Participants With Central Precocious Puberty
LIBELULA™: An Open-label, Single-arm, Multi-center, Phase 3 Study on the Efficacy, Safety, and Pharmacokinetics of Debio 4326, a Triptorelin 12-month Formulation, in Pediatric Participants With Central Precocious Puberty
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants with central precocious puberty (CPP).

View All Clinical Trials

Related Latest Advances

Role of triptorelin and single fixed-time artificial insemination on productive and reproductive performance of hyperprolific sows.
Role of triptorelin and single fixed-time artificial insemination on productive and reproductive performance of hyperprolific sows.
Journal: Veterinary and animal science
Published: September 19, 2025
Commentary on "Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate".
Commentary on "Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate".
Journal: Annals of pediatric endocrinology & metabolism
Published: September 08, 2025
AQbD-based development of a stability-indicating UHPLC-PDA-QDa method for triptorelin in parenteral formulations.
AQbD-based development of a stability-indicating UHPLC-PDA-QDa method for triptorelin in parenteral formulations.
Journal: Analytical methods : advancing methods and applications
Published: July 30, 2025
View All Latest Advances

Brand Information

TRIPTODUR (triptorelin)
1OVERDOSAGE
There is no experience with overdosage in clinical trials of triptorelin. If overdosage occurs, therapy should be discontinued and appropriate supportive and symptomatic treatment administered.
2HOW SUPPLIED/STORAGE AND HANDLING
Each TRIPTODUR 22.5 mg single-use kit (NDC 24338-150-20) contains:
  • One single-dose vial of TRIPTODUR 22.5 mg (NDC 24338-150-01) with a Flip-Off seal containing sterile lyophilized white to slightly yellow powder cake
  • One sterile, glass syringe with Luer Lock prefilled with 2 mL of Sterile Water for Injection (NDC 24338-150-02)
  • Two sterile 21 gauge, 1½" needles (
  • One Package Insert
3PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information and Medication Guide).